Application progress of laser photocoagulation in diabetic retinopathy treatment in the era of anti-vascular endothelial growth factor agents
10.3980/j.issn.1672-5123.2023.8.09
- VernacularTitle:抗VEGF时代激光光凝治疗糖尿病视网膜病变的应用进展
- Author:
Ke-Ke HU
1
;
Yan-Nian HUI
1
;
Hong-Jun DU
1
Author Information
1. Eye Institute of PLA;Department of Ophthalmology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
laser photocoagulation;
diabetic retinopathy;
vascular endothelial growth factor(VEGF);
treatment
- From:
International Eye Science
2023;23(8):1285-1289
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy(DR)is the most prevalent and severe ocular complication in people with diabetes, and it is one of the leading causes of blindness in adults. In recent years, drug therapy represented by anti-vascular endothelial growth factor(VEGF)agents has become the first-line therapy in DR treatment, but it cannot reverse retinal non-perfusion areas, microaneurysms and abnormal teleangiectatic capillaries, those who cannot be treated on time are at risk of disease progression. Laser photocoagulation has been widely applied for more than 40 years, it can effectively reduce the rate of blindness by eliminating the non-perfusion areas of capillaries, and panretinal photocoagulation(PRP)has been the primary treatment for DR. With the continuing innovations in laser technology, on the basis of maintaining the curative effect, the aim of minimizing retinal damage and adverse side effects has been realized. A combination of laser photocoagulation and anti-VEGF agents can achieve complementary advantages and better efficacy. Deepening the clinical research on laser therapy and laser therapy combined with anti-VEGF agents in the treatment of DR may help to establish the personalized treatment corresponds with our national conditions. This article briefly reviews the latest application progress of laser therapy in DR treatment in the era of anti-VEGF agents.
